News

May 2, 2023
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
April 10, 2023
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
March 31, 2023
TScan Therapeutics Announces CEO Transition
March 14, 2023
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
March 13, 2023
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
March 8, 2023
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
March 1, 2023
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
February 21, 2023
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
January 23, 2023
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
January 5, 2023